DARA Bio Rapped By FDA for Omitting Drug Risks in Sales Aid

Drug Industry Daily
A A
The FDA, showing no signs of easing its advertising and marketing enforcement, has rapped DARA BioSciences for omitting risk information about its cancer drug Soltamox in a sales aid.

To View This Article:

Login

Subscribe To Drug Industry Daily